Processa Pharmaceuticals transitioned Chief Development and Regulatory Officer Dr. Sian Bigora to part-time, effective May 1, 2026, as part of her planned retirement.
Key takeaways
Dr. Bigora transitions from full-time executive to part-time employee effective May 1, 2026.
She will no longer be an executive officer under Section 16 of the Exchange Act.
She retains her title of Chief Development and Regulatory Officer.
Her existing employment agreement terminates and is replaced by a new part-time arrangement.
Previously granted equity awards and bonus compensation remain unchanged.